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Clocortolone pivalate (Purantix(R) 
Sandoz) is a new dihalogenated cortico-
steroid for topical use, 9a-Chloro-6a-fluoro-
II,e, 21-dihydroxy-16a methyl-pregna-1, 4-
diene-3,20-dione 21 pivalate. Its anti-
inflammatory action and good tolerance 
have been demonstrated in animal experi-
ments. In the granuloma-pouch test, its act-
ivity when administered by the oral or sub-
cutaneous route has been shown to be 
approximately thirty times that of hydro-
cortisone acetate. An open clinical triai was 
undertaken to evaluate its efficacy and 
tolerance, when used at a concentration of 
0.1 % in an oil-in-water base, in dermatoses 
normally responsive to topical corticoste-
roids. . 
Method 
One hundred and one patients with the 
following diagnoses were treated: 
Psoriasis vulgaris (20) 
Contact dermatitis (23) 
Lichen chronicus simplex (9) 
Atopic dermatitis (6) 
Pompholyx (3) 
Seborrhoeic eczema (2) 
Nummular eczema (2) 
Pruritus in association with varicose 
veins (I) 
Infective dermatitis (I) 
Acne vulgaris (9) 
Keloid scars (8) 
Pruritus ani (5) 
Herpes simplex (I) 
Pityriasis rubra pilaris (I) 
Dermatitis papillaris capilliti (2) 
Fifty-three of these patients were male 
and forty-eight female. Only five were in-
patients. Ages ranged from 3 months'to 75 
years but 87 were over 14. The cream was 
applied two to four times daily, in con-
formity with normal practice,and was con-
tinued until its maximum effect was 
deemed to have been achieved. This 
averaged 26.7 days (range 8-51 days). Two 
patients only were treated for part of the 
time with occlusive dressings which were 
changed 3 and 7 times per week respec-
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Diagnosis Acute-weeping Acute Sub-acute Chronic Total 
Psoriasis vulgaris 1 9 10 20 
Eczema 1 8 32 6 47 
Others 4 19 11 34 
TABLE I 
tively. Both were cases of psoriasis. Dur-
ing the trial period, no other topical 
medicaments were applied except for 
potassium permanganate lotions or baths. 
No antibiotics or systemic steroids were 
administered. 
Assessment 
For the purposes of evaluation, cases 
were grouped into three categories, viz 
psoriasis vulgaris, eczema (including con-
tact dermatitis, lichen chronicus simplex, 
pompholyx, atopic dermatitis, seborrhoeic 
eczema, nummular eczema, pruritus 
associated with varicose veins, and infec-
tive dermatitis) and 'other indications' 
(acne vulgaris, keloid scars, pruritus ani, 
Effectiveness Eczema 
discoid lupus erythematosus, herpes sim-
plex, pityriasis rubra pilaris, lichen planus, 
and dermatitis papillaris capilliti). Table 
I summarises the diagnostic distribution 
of the patients and the state of the lesions 
they exhibited. 
Assessment of efficacy was based on: 
a) recording of the following target 
symptoms on a four-point severity 
scale before and after treatment: 
erythema, weeping, scaling, pruri-
tus, lichenification; 
b) overall assessments at the end of the 
trial by the investigator and the 
patients separately of efficacy on a 
five-point scale. 
Local and general side effects were 
also recorded. 
Psoriasis Other indications 
Physician Patient Physician Patient Physician Patient 
very 
effective 25 35 2 9 9 16 
effective 21 10 7 5 8 4 
moderately 
effective 1 2 9 4 9 8 
slightly 
effective 1 1 3 
not 
effective 1 1 5 6 
TOTAL 47 20 34 
TABLE 11 Overall Assessment 
,I 
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Diagnosis Erythema Weeping 
Eczema 70.7% 100% 
(41) (10) 
Psoriasis 20.0% 
(20) 
Other indciations 35.7% 
(28) 
Scaling 
92.3% 
(26) 
44.4% 
(18) 
50.0% 
(6) 
Pruritus 
92.5% 
(40) 
100% 
(11) 
Lichenifications 
87.7% 
(7) 
50.0% 
(2) 
TABLE III Percentage of Patients with Complete Regression of Symptoms 
Numbers in brackets refer to number of cases showing each symptom at 
start of trial. 
Results 
Clocortolone was judged by the inves-
tigator as being effective or very effective 
in 71.3% of cases. It was considered 
moderately effective in another 18.7% 
and ineffective or only slightly effective in 
the remaining 9.9% (Table II). 
Target symptoms in eczema resolved 
completely in between 70.7% (for erythe-
ma) and 100% (for weeping) of cases. 
Pruritus was relieved in 92.5% of cases 
of eczema and in 100% of the 'other indi-
cations'. 
Average scores for target symptoms 
before and after treatment were calculated 
and the differences between pretreatment 
and post-treatment average scores were 
examined for significance by the t-test. 
The differences were highly significant in 
eczema for erythema, scaling and pruritus, 
and in psoriasis for both erythema and 
scaling (Table IV). 
Discussion 
In the eczemas, treatment was effec-
tive or very effective in no less than 4:6 
of the 47 cases studied. In the remaining 
patient, clocortolone \was 'judged moder-
ately effective. In psoriasis, treatment was 
considered to be very effective in only 2 
cases out of the 20 as judged by the 
investigator. Nevertheless, the improve-
ment of both target symptoms was statis-
tically highly significant and it is note-
worthy that in the opinion of the patients 
the treatment was very effective in 9 
cases, effective in 5 and moderately effec-
tive in 4, only in one case being slightly 
effective and in 1 ineffective. Not un-
expectedly, clocortolone proved disap-
pointing in 'acne vulgaris and in keloid 
scars. In eight cases of keloid, treatment 
was moderately effective in 4, and slightly 
effective or ineffective in the other 4. In 
acne vulgaris, it was very effective in one 
case, effective in three cases, moderately 
effective in one case and slightly effective 
or ineffective in the remaining four. In 
the 5 cases of discoid lupus erythematosus, 
treatment was effective in 4 and very ef-
fective in 1. The result in the one case of 
herpes simplex was assessed as very effec-
tive. Of particular interest was the one 
case of pityriasis rubra pilaris who had 
been attending the clinic for 13 years and 
received numerous treatments without any 
effect but who responded rapidly and 
dramatically to clocortolone with com-
plete resolution. The most striking ex-
perience in the trial of this new product 
was its effectiveness in pruritic states. In 
all 5 cases of pruritus ani relief was com-
plete, prompt and enduring although most 
of them were long-standing. Of the 40 
cases of eczema which presented with pru-
ritus, 37 (92.5%) attained complete reso-
lution of this symptom. There were no 
general side effects in any patients. The 
only local side effect encountered was a 
mild local irritation in one patient only. 
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Average Score 
Diagnosis Symptom Difference t-Test 
Pre-treatment Post-treatment 
Erythema 2.0 0.3 -1.7 highly sig-
nificant 
Weeping 1.9 0.0 -1.9 significant 
Eczema Scaling 1.6 0.1 -1.5 highly sig-
nificant 
Pruritus 2.2 0.1 -2.1 highly sig-
nificant 
Lichenification 1.7 0.1 -1.6 not signi-
ficant 
Erythema 2.0 0.9 -1.1 highly signi-
Psoriasis ficant 
Scaling 2.2 0.7 -1.5 
Erythema 1.9 0.8 -1.1 
Scaling 1.7 0.5 -1.2 not tested 
Other due to small 
Indications Pruritus 2.3 0.0 -2.3 numbers of 
each indica-
Lichenification 2.0 1.0 -1.0 tion 
TABLE IV Significance of differences between pre- and post-treatment average scores. 
Summary 
In a study of 101 cases, clocortolone 
was shown to be highly elffective in the 
treatment of various forms of e1ezema and 
dermatitis. It was also shown to bel effec-
tive 01' moderately effective in most cases 
of psoriasis. There were mixe1d results in 
a heterogenous group of 34 patients with 
other indications. Outstanding bene1fit was 
obtained in the relief of pruritus in all 
conditions in which this symptom oc-
cUlTed, and particularly in pruritus ani. 
L<>ical and s)'istematic tolerance was exlcel-
lent. 
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